Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:ELVNNASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.47-2.0%$8.10$5.20▼$10.67$1.17B1.151.35 million shs2.12 million shsELVNEnliven Therapeutics$20.06-3.0%$19.39$13.30▼$30.03$1.01B0.79291,051 shs352,463 shsWVEWAVE Life Sciences$6.50-2.5%$6.71$4.87▼$16.74$1.04B-1.041.28 million shs850,813 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+11.20%+9.92%+7.46%+51.31%ELVNEnliven Therapeutics0.00%-2.91%+15.92%+5.08%-11.51%WVEWAVE Life Sciences0.00%+1.52%+9.70%-17.45%+33.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.5163 of 5 stars3.51.00.00.02.00.81.9ELVNEnliven Therapeutics2.2379 of 5 stars3.50.00.00.02.54.20.0WVEWAVE Life Sciences4.3065 of 5 stars3.51.00.04.81.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5035.77% UpsideELVNEnliven Therapeutics 3.00Buy$39.6097.41% UpsideWVEWAVE Life Sciences 2.92Moderate Buy$20.50215.38% UpsideCurrent Analyst Ratings BreakdownLatest IMU, AUPH, ELVN, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.004/29/2025WVEWAVE Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/8/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.87$0.30 per share28.01$2.68 per share3.16ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AWVEWAVE Life Sciences$108.30M9.34N/AN/A$1.37 per share4.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2830.2515.13N/A16.11%14.27%9.93%7/30/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/6/2025 (Estimated)Latest IMU, AUPH, ELVN, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26ELVNEnliven TherapeuticsN/A21.0721.06WVEWAVE Life SciencesN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%ELVNEnliven Therapeutics95.08%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%ELVNEnliven Therapeutics25.90%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableWVEWAVE Life Sciences240155.56 million118.26 millionOptionableIMU, AUPH, ELVN, and WVE HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Given Outperform Rating at WedbushJune 24, 2025 | americanbankingnews.comWhere WAVE Life Sciences Stands With AnalystsJune 23, 2025 | benzinga.comWAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from WedbushJune 23, 2025 | marketbeat.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...June 22, 2025 | manilatimes.netMWave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association MeetingJune 22, 2025 | nasdaq.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...June 20, 2025 | finance.yahoo.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific SessionsJune 20, 2025 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?June 20, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?June 19, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in StockJune 14, 2025 | insidertrades.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 SharesJune 13, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Now Covered by Raymond JamesJune 11, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from AnalystsJune 11, 2025 | marketbeat.comBrokers Offer Predictions for WVE FY2026 EarningsJune 10, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's WhyJune 9, 2025 | marketbeat.comTwo Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)June 3, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)June 2, 2025 | marketbeat.comNuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 31, 2025 | marketbeat.comWave Life Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical OfficerMay 28, 2025 | globenewswire.comIs Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMU, AUPH, ELVN, and WVE Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.47 -0.17 (-1.97%) As of 04:00 PM EasternAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Enliven Therapeutics NASDAQ:ELVN$20.06 -0.62 (-3.00%) As of 04:00 PM EasternEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.WAVE Life Sciences NASDAQ:WVE$6.50 -0.17 (-2.55%) As of 04:00 PM EasternWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
